Document:

Exhibit 10.16

 

[Letterhead of Fusion Fuel Green]

 

[Director name]

[Address]

 

[Date]

 

Re: Fusion Fuel Green plc (the “Company”)

 

Dear ●

 

I am pleased to confirm that following
the recommendation of the nominating committee, the board of directors of the Company (the “Board”) has approved
your appointment as an independent non-executive director of the Company subject to you confirming that you accept the terms and
conditions set out in this letter. This letter sets out the main terms of your appointment.

 

It is agreed that, on acceptance of this
offer, this letter will constitute a contract for services and not a contract of employment.

 

		1.	APPOINTMENT

 

		1.1	You will be a “Class III Director”. Subject to the remaining provisions of this letter,
your appointment is for an initial term commencing on closing (“Closing”) of the Business Combination Agreement
dated 6 June 2020 (as amended and restated on August 25, 2020, and as may be further amended from time to time) between, among
others, the Company, HL Acquisitions Corp. and Fusion Welcome – Fuel, S.A., and terminating on the conclusion of the Company’s
2023 Annual General Meeting1 (“AGM”),
unless terminated earlier by either party by giving the other party prior written notice or by an ordinary resolution of the shareholders
of the Company.

 

		1.2	Your appointment is subject to the constitution of the Company as is currently in effect and as
may be modified or amended from time to time (the “Constitution”). Nothing in this letter will be taken to exclude
or vary the terms of the Constitution as it applies to you as a director of the Company. Your continued appointment as non-executive
director is subject to election by the Company’s shareholders at the 2023 AGM and to re-election at any subsequent AGM at
which either the Constitution requires, or the Board resolves, that you stand for re-election.

 

If the shareholders do not re-elect
you as a director, or you otherwise cease to be a director in accordance with the Constitution, your appointment will terminate
automatically, with immediate effect and without compensation thereafter.

 

		1.3	Continuation of your service as a director is also contingent on satisfactory performance, as determined
by the nominating committee of the Board, and any relevant statutory provisions relating to the removal of a director.

 

		1.4	The nominating committee of the Board may nominate you to serve for successive term(s), in its
discretion and subject to your agreement and your re-election at the AGM in accordance with the Constitution. Notwithstanding any
mutual expectation, you have no right to re-nomination by the Board, either annually or after any three-year period.

 

 

 

		1	NTD: this provision will be tailored to each director.

 

     

     

    

 

		1.5	You may be appointed to serve on one or more committees of the Board. You have been appointed to,
and have agreed to serve on, the [●] committee during your initial term of service.2
The [●] committee charter is included as Exhibit A hereto.

 

		1.6	The Company’s Code of Ethics is included as Exhibit B hereto. You agree to comply
with the Code of Ethics, as may be amended from time to time.

 

		1.7	Notwithstanding paragraphs 1.1–1.6, we may terminate your appointment with immediate effect
if you:

 

		(a)	commit a material breach of your obligations under this letter;

 

		(b)	commit any serious or repeated breach or non-observance of your obligations to the Company (which
include an obligation not to breach your duties to the Company, whether statutory, fiduciary or common law);

 

		(c)	are guilty of any fraud or dishonesty or have acted in a manner which, in the opinion of the Company
acting reasonably, brings or is likely to bring you or the Company into disrepute or is materially adverse to the interests of
the Company;

 

		(d)	are convicted of any arrestable criminal offence other than an offence under road traffic legislation
anywhere in the world for which a fine or non-custodial penalty is imposed;

 

		(e)	are restricted or disqualified from acting as a director of any company;

 

		(f)	in the opinion of the majority of the Board, become incapable by reason of mental disorder of discharging
your duties as a director;

 

		(g)	have been absent for more than six consecutive months without permission of the Board from meetings
of the directors held during that period and your alternate director (if any) will not have attended any such meeting in your place
during such period and all of your co-directors pass a resolution that by reason of such absence you have vacated your office;

 

		(h)	are required in writing (whether in electronic form or otherwise) by all your co-directors to resign;
or

 

		(i)	have not complied with the Company’s anti-corruption and bribery policy and procedures or
any applicable bribery or corruption legislation.

 

		1.8	On termination of your appointment, you will at the request of the Company resign from your office
as a director of the Company.

 

 

 

 

2
NTD: Include all committees to which the relevant director is being appointed.

 

    2

     

    

 

		1.9	Your status during your term of service as a director will be that of an independent contractor
and not an employee of the Company.

 

		2.	TIME COMMITMENT

 

		2.1	You will be expected to spend a sufficient amount of time as may be necessary for the Board to
address matters relating to the Company’s investment policy and the use of funds raised by the Company from time to time
and to attend any meetings of the Board as may be called from time to time. You will be expected to devote such time as is necessary
for the proper performance of your duties and you should be prepared to attend quarterly board meetings (at which directors will
be asked to approve the filing with the SEC of annual and interim financial statements and the company’s annual report on
Form 20-F) as well as another board meeting called for the purposes of reviewing and approving the Company’s budget for the
subsequent year.

 

		2.2	Meetings may involve you in some overseas travel, the expenses of which will be reimbursed by the
Company in accordance with normal payroll practices. In addition, you will be required to consider all relevant papers before each
meeting. Unless urgent and unavoidable circumstances prevent you from doing so, it is expected that you will attend the meetings
outlined above.

 

		2.3	The nature of the role makes it impossible to be specific about the maximum time commitment, and
there is always the possibility of additional time commitment in respect of preparation time and ad hoc matters which may arise
from time to time, and particularly when the Company is undergoing a period of increased activity. At certain times it may be necessary
to convene additional Board, committee or shareholder meetings.

 

		2.4	The time commitment will increase should you become a committee member or chair, or if you are
given additional responsibilities.

 

		2.5	By accepting this appointment you undertake that, taking into account all other commitments you
may have, you are able to, and will, devote sufficient time to your duties as a director.

 

		3.	Role and DUTIES

 

		3.1	The Board as a whole is collectively responsible for the success of the Company. The Board’s
role is to:

 

		(a)	provide oversight of the Company within a framework of prudent and effective controls which enable
risk to be assessed and managed;

 

		(b)	in conjunction with management, set the Company’s strategic aims, ensure that the necessary
financial and human resources are in place for the Company to meet its objectives, and review management performance; and

 

		(c)	in conjunction with management, set the Company’s values and standards and ensure that its
obligations to its shareholders and others are understood and met.

 

		3.2	As a non-executive director you will have the same general legal responsibilities to the Company
as any other director. You will be expected to perform your duties, whether statutory, fiduciary or common law, faithfully, efficiently
and diligently to a standard commensurate with both the functions of your role and your knowledge, skills and experience.

 

    3

     

    

 

		3.3	You will exercise your powers in your role as a director having regard to relevant obligations
under prevailing law and regulation, including, without limitation, the Companies Act 2014 (the “Act”), the
rules and regulations of the Securities and Exchange Commission (“SEC”), and the rules of the Nasdaq Stock Market
(“Nasdaq”).

 

		3.4	You will have particular regard to the general duties of directors in Part 5 of the Act, including
the duty of each director of a company to ensure that the Act is complied with by the Company. In addition, you must:

 

		(a)	act in good faith in what you, as a director of the Company, consider to be the interests of the
Company;

 

		(b)	act honestly and responsibly in relation to the conduct of the affairs of the Company;

 

		(c)	act in accordance with the Company’s Constitution and exercise your powers as a director
only for the purposes allowed by law;

 

		(d)	not use the company’s property, information or opportunities for your own or anyone else’s
benefit unless:

 

		(i)	this is expressly permitted by the Company’s Constitution; or

 

		(ii)	the use has been approved by a resolution of the Company in general meeting;

 

		(e)	not agree to restrict your power as a director to exercise an independent judgement unless:

 

		(i)	this is expressly permitted by the Company’s Constitution; or

 

		(ii)	the director’s agreeing to such has been approved by a resolution of the company in general
meeting;

 

		(f)	avoid any conflict between your duties to the Company and your other (including personal) interests
unless you are released from your duty to the Company in relation to the matter concerned, whether in accordance with provisions
of the Company’s Constitution or by a resolution in general meeting;

 

		(g)	exercise the care, skill and diligence which would be exercised in the same circumstances by a
reasonable person having both:

 

		(i)	the knowledge and experience that may reasonably be expected of a person in the same position as
you; and

 

		(ii)	the knowledge and experience which you have; and

 

		(h)	in addition to the duty under Section 224 of the Act (duty to have regard to the interests of the
Company’s employees in general), have regard to the interests of the Company’s shareholders.

 

    4

     

    

 

		3.5	In your role as a director you will be required to:

 

		(a)	constructively challenge proposals on strategy;

 

		(b)	scrutinise the performance of management in meeting agreed goals and objectives and monitor the
reporting of performance;

 

		(c)	satisfy yourself that the Company has processes in place to ensure the integrity of financial information
and that financial controls and systems of risk management are robust and defensible;

 

		(d)	subject to the authority delegated to the compensation committee, determine appropriate levels
of remuneration of executive directors, if any, and have a prime role in appointing and, where necessary, removing any executive
directors, and in succession planning;

 

		(e)	devote time to developing and refreshing your knowledge and skills;

 

		(f)	uphold high standards of integrity and probity and support me and the other directors in instilling
the appropriate culture, values and behaviours in the boardroom and beyond;

 

		(g)	take into account the views of shareholders where appropriate;

 

		(h)	exercise relevant powers under, and abide by, the Constitution;

 

		(i)	exercise your powers as a director in accordance with the Company’s policies and procedures
and internal control framework or any applicable bribery or corruption legislation; and

 

		(j)	not do anything that would cause you to be disqualified from acting as a director under the Act,
Constitution, rules and regulations of the SEC, or Nasdaq rules.

 

		3.6	You will disclose any direct or indirect interest which you may have in any matter being considered
at a Board meeting or committee meeting and, save as permitted under the Constitution and the Company’s Code of Ethics, you
will not vote on any resolution of the Board, or of one of its committees, on any matter where you have any direct or indirect
interest.

 

		3.7	You will immediately report to me your own wrongdoing or the wrongdoing or proposed wrongdoing
of any employee (where any) or director of which you become aware.

 

		3.8	Unless specifically authorised to do so by the Board, you will not enter into any legal or other
commitment or contract on behalf of the Company.

 

		3.9	You will be entitled to request all relevant information about the Company’s affairs as is
reasonably necessary to enable you to discharge your responsibilities as a non-executive director.

 

    5

     

    

 

		4.	FEES AND EXPENSES

 

		4.1	You will be paid an annual fee of €25,0003
gross (current at the date of this letter) (“Cash Compensation”). The Cash Compensation will be paid each year
of your service as a director, quarterly in advance, after deduction of any taxes and other amounts that are required by law.

 

		4.2	You will also be entitled to 15,000 Class A Ordinary Shares in the Company for every three years
served on the Board (“Director Shares”). The Director Shares (other than the initial Director Shares granted
pursuant to paragraph 4.5 below) will be granted pursuant to and subject to an equity incentive plan of the Company.

 

		4.3	You shall not sell, transfer, or otherwise dispose of your Director Shares, except to Permitted
Transferees (defined below), until such shares have vested and any relevant lockup period has expired. Director Shares vest in
three equal instalments of 5,000 Director Shares on each annual meeting of shareholders during the term of your service; provided
that the first tranche of 5,000 Director Shares are fully vested as of the Closing.

 

		4.4	For the avoidance of doubt, for your initial term as a Class III director4,
you will be granted 15,000 Director Shares fully vested as of Closing, 5,000 of which shall not be subject to any lockup, 5,000
of which will be subject to a lockup that expires at the Company’s annual general meeting in 2021, and 5,000 of which will
be subject to a lockup that expires at the Company’s annual general meeting held in 2022. Any shares granted to you for any
subsequent term you serve as a director will be issued pursuant to an equity incentive plan and will be subject to a vesting schedule.

 

		4.5	As used herein, “Permitted Transferee” means (i) the Company or an affiliate
of the Company, (ii) a member of your immediate family or a trust, the beneficiary of which is you or a member of your immediate
family, who receives Director Shares by bona fide gift for estate planning purposes, (iii) a person who receives Director Shares
from you by virtue of the laws of descent and distribution upon your death, or (iv) a person who receives Director Shares from
you pursuant to a qualified domestic relations order binding on you. As used herein, “immediate family” means
a spouse, parent, lineal descendants, the spouse of any lineal descendent, brothers or sisters, or a trust, all of whose current
beneficiaries are members of your immediate family.

 

		4.6	You will also be entitled to participate in any incentive plans that may be adopted by the Company
from time to time. Any incentive payments made to you as an independent non-executive director shall be recommended by the compensation
committee and approved by the Board.

 

		4.7	Fees will be subject to periodic review by the compensation committee of the Board.

 

		4.8	You will comply with the Company’s requirements regarding the minimum shareholding level,
if any (agreed from time to time by the Board).

 

 

 

 

3
NTD: To be updated for the Chariman’s agreement for €50,000, and audit committee head €35,000

4
NTD: this provision will be tailored to each director.

 

    6

     

    

 

		4.9	The Company will reimburse you for all reasonable and properly-documented expenses you incur in
performing the duties of your office. The procedure and other guidance in respect of expense claims is set out in the Company’s
guide relating to expense claims from time to time or, if no such guide is in place, as agreed with the Chairman of the Board.

 

		4.10	Unless otherwise agreed between you and the compensation committee of the Board, on termination
of your services as a director (i) you will only be entitled to such fees as may have accrued to the date of termination, together
with reimbursement in the normal way of any expenses properly incurred prior to that date and (ii) you will forfeit any unvested
Director Shares.

 

		5.	INDEPENDENCE AND OUTSIDE INTERESTS

 

		5.1	The Board of the Company has determined you to be independent, taking account of the guidance contained
in Nasdaq Rule 5605 and IM-5605, and taking into account exemptions thereto at Nasdaq Rule 5615.5

 

		5.2	It is accepted and acknowledged that you have business interests other than those of the Company.
The Company expressly acknowledges that you (i) are or may become a full-time employee of another entity and that your responsibilities
to such entity must have priority over your responsibilities to the Company and (ii) sit or may sit on the board of directors of
other entities, subject to any limitations set forth in the Sarbanes-Oxley Act of 2002 and the rules of Nasdaq.

 

		5.3	Notwithstanding the foregoing, you acknowledge the importance of avoiding conflicts of interest
and the appearance of conflicts of interest. Accordingly, you have disclosed all present or currently existing conflicts and agree
to disclose to the Company any future commitments, whether such commitments create potential or actual conflicts of interest or
the appearance of any conflicts. In the event that you become aware of any further potential or actual conflicts of interest, these
should be disclosed to me as soon as they become apparent and the agreement of the Board may have to be sought. You should immediately
recuse yourself from decision making on any matter on which there is a conflict.

 

		5.4	You represent to the Company that your execution and performance of your duties as a director of
the Company do not and will not violate any agreement or obligation, whether written or not, that you may have with or to any person,
including without limitation any prior or current employer.

 

		6.	CONFIDENTIALITY

 

		6.1	You acknowledge that all information acquired during your appointment is confidential to the Company
and should not be released, communicated, or disclosed either during your appointment or following termination (by whatever means),
to third parties without my prior clearance.

 

		6.2	This restriction will cease to apply to any confidential information which may (other than by reason
of your breach) become available to the public generally.

 

 

 

 

5
NTD: This provision will be tailored to each director.

 

    7

     

    

 

		6.3	You acknowledge the need to hold and retain Company information (in whatever format you may receive
it) under appropriately secure conditions.

 

		6.4	You will notify the Company promptly if you are subpoenaed or otherwise served with legal process
in any manner involving the Company.

 

		6.5	In the event of any claim or litigation against the Company, or any officer, employee, or director
of the Company, based upon any alleged conduct, acts or omissions, you will cooperate with the Company and provide to the Company
such information and documents in your possession or control as are necessary and reasonably requested by the Company or its counsel.

 

		6.6	Nothing in this paragraph will prevent you from disclosing information which you are entitled to
disclose under any statutory provision, provided that the disclosure is made in accordance with the provisions of such statutory
provision.

 

		7.	PRICE SENSITIVE INFORMATION AND DEALING IN THE COMPANY’S SHARES

 

		7.1	You understand that by virtue of the grant of Director Shares, along with any other ordinary shares
of the Company which you may own, directly or indirectly, you have an interest in the shares in the Company which will be disclosable
on your appointment under the requirements in Chapter 5 of Part 5 of the Act. As the definition of a disclosable interest is very
broad under Chapter 5 of Part 5 of the Act, it is important that you inform the Company Secretary immediately if you, or a person
connected with you, acquires any interest whatsoever in any shares in the Company.

 

		7.2	In addition, all five percent (5%) shareholders of the Company are required to file beneficial
ownership reports under the Section 13 of the Securities Exchange Act of 1934, as amended (“Exchange Act”).
Those persons and entities who are already five percent shareholders must file a Schedule 13G within 45 days after the calendar
year in which the Company’s Registration Statement became effective (i.e., by February 14, 2021). Follow-up filings
on Schedule 13G are due within 45 days of each succeeding year if the shareholder has acquired or disposed of any stock during
the previous year.

 

		7.3	Your attention is drawn to the requirements under both law and regulation regarding the disclosure
of price sensitive information, and in particular to the prohibition against trading in the Company’s securities while in
possession of material non-public information (“insider trading”). The Company’s Insider Trading Policy is attached
as Exhibit C. If you have any questions, please contact me.

 

		8.	INDUCTION

 

The Company has provided you
with a comprehensive, formal and tailored induction on your original appointment. Should you have any queries on your duties and
obligations please raise the same with the Company Secretary who can arrange for further information and training to be provided
as required.

 

		9.	REVIEW PROCESS

 

The performance of individual
directors and the whole Board and its committees is evaluated annually. Further details will be provided as part of the induction
process.

 

    8

     

    

 

		10.	INSURANCE AND INDEMNITY

 

		10.1	The Company has directors’ and officers’ liability insurance (D&O) in place and
it is intended to maintain such cover for the full term of your appointment. You have been informed of the current indemnity limit,
on which the Board is updated from time to time. Other details of the cover are available from the Company Secretary.

 

		10.2	The Company shall cooperate in all respects to ensure that you have access all available insurance
coverage and shall do nothing to damage your status as an insured, and shall provide all necessary information for you to make
or tender any claim under applicable coverage.

 

		10.3	You are a party to an Indemnification Agreement with the Company, pursuant to which the Company
has granted you a deed of indemnity against certain liabilities that may be incurred as a result of your office to the extent permitted
by Section 235 of the Act.

 

		11.	INDEPENDENT PROFESSIONAL ADVICE

 

Circumstances may occur when,
in the execution of your duties as a director, it will be appropriate for you to seek advice from independent advisers at the Company’s
expense. The Company will reimburse the reasonable cost of expenditure incurred by you in such circumstances in accordance with
any policy in effect from time to time.

 

		12.	CHANGES TO PERSONAL DETAILS

 

You will advise the Company Secretary
promptly of any change in address or other personal contact details.

 

		13.	RETURN OF PROPERTY

 

Upon termination of your service
as a director of the Company (for whatever cause), you will deliver to the Company or destroy, at the Company’s discretion,
all documents, records, papers or other Company property which may be in your possession or under your control, and which relate
in any way to the Company’s business affairs, and you will not retain any copies thereof.

 

		14.	DATA PROTECTION

 

		14.1	The Company may obtain, hold and
process data about you in accordance with applicable data protection legislation (that is: (a) the General Data Protection Regulation
(EU) 2016/679 (the “GDPR”) and any national implementing law, regulations and secondary legislation, as amended
or updated from time to time in Ireland; and (b) any successor legislation to the GDPR or the Data Protection Acts 1998 and 2018)
for the purposes set out in the Company’s data privacy notice, a copy of which is available at ● (the “Data
Privacy Notice”).

 

		14.2	The Company may, in accordance with the Data Privacy Notice, make such information available to
other officers of the Company or to other third parties, whether or not outside the European Economic Area, for administration
purposes and other purposes in connection with your appointment, where it is necessary or desirable for the Company to do so in
the company’s legitimate interests.

 

		14.3	You will comply with your data protection obligations as set out in the Data Privacy Notice.

 

    9

     

    

 

		14.4	The Company may change the Data Privacy Notice at any time and will notify you in writing of any
changes.

 

		15.	MUTUAL NON-DISPARAGEMENT

 

You and the Company each agree
not to make, cause to be made, publish, communicate, ratify, or endorse any disparaging remarks, derogatory statements or comments
to any person with respect to the other party or its current, former, or prospective business, employees, or officers, anywhere
in the world, at any time, whether during or after your appointment as a director.

 

		16.	Entire agreement

 

		16.1	This letter and any document referred to in it constitutes the entire terms and conditions of your
appointment and supersedes all previous discussions, correspondence, negotiations, arrangements, understandings and agreements
between you and the Company relating to its subject matter.

 

		16.2	You agree that you will have no remedies in respect of any representation or warranty (whether
made innocently or negligently) that is not set out in this letter and you will not have any claim for innocent or negligent misrepresentation
based on any statement in this letter.

 

		17.	Variation

 

No variation or modification
of this letter will be effective unless it is in writing and signed by you and the Company (or respective authorised representatives).
The failure to enforce at any time the provisions of this letter or to require at any time performance by the other party hereto
of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity
of this letter or any part hereof, or the right of either party hereto to enforce each and every provision in accordance with its
terms. No waiver by either party hereto of any breach by the other party hereto of any provision of this letter to be performed
by such other party shall be deemed a waiver of similar or dissimilar provisions at that time or at any prior or subsequent time.

 

		18.	Governing law and DISPUTE RESOLUTION

 

		18.1	Your appointment with the Company and any dispute or claim arising out of or in connection with
it or its subject matter or formation (including non-contractual disputes or claims) will be governed by and construed in accordance
with the laws of Ireland.

 

		18.2	Any dispute or claim arising out of or relating to your appointment shall be determined by arbitration
administered by the International Centre for Dispute Resolution in accordance with its International Arbitration Rules.  All
disputes shall be heard by a single arbitrator. The place of arbitration shall be Dublin, Ireland. The arbitration hearing may
take place by way of videoconference. The language of the arbitration shall be English. Except as may be required by law,
neither a party nor its representatives may disclose the existence, content, or results of any arbitration hereunder without the
prior written consent of all parties. The arbitration award shall be final and binding on the parties, and the parties undertake
to carry out any award without delay.  Judgment upon the award may be entered by any court having jurisdiction of the award
or having jurisdiction over the relevant party or its assets.

 

    10

     

    

 

If you are agreeable to accepting your
appointment on the foregoing terms and conditions, I would ask you to sign and return one copy of this letter to me. Upon receiving
it from you I will send you the necessary forms for completion which are required to be sent to the Companies Registration Office
or maintained with the Company’s records.

 

	
        Yours sincerely
	 
	 	 
		 
	[Chairperson]	 

 

 

 

 

 

I confirm and agree to the terms of my
appointment as a non-executive director of the Company as set out in this letter.

 

		 
	[Insert name of Director] 	 
	 	 
	Date:  	 

 

 

11EX-4.4

 Exhibit 4.4 

FORM OF WARRANT 
 THIS WARRANT AND THE UNDERLYING
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED UNLESS
(A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES, (B) THE SALE IS MADE IN ACCORDANCE WITH RULE 144 UNDER THE ACT, OR (C) THE COMPANY RECEIVES AN OPINION OF COUNSEL FOR THE HOLDER OF SUCH
SECURITIES STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT FROM REGISTRATION UNDER THE ACT. 
 ARKO CORP. WARRANT

  

			
	Warrant No.: [    ]	  	Issued on [_______], 2020
		  	[_______] Warrant Shares

 THIS CERTIFIES THAT, for value received, [WARRANT
HOLDER] (or a permitted transferee thereof) (the “Holder”) is entitled, subject to the terms and conditions of this Warrant, to purchase from ARKO Corp., a Delaware corporation (the
“Company”), at the applicable Warrant Price (as defined below) up to that number of fully paid and non-assessable Warrant Shares, subject to adjustment from time to time as set forth in
Section 6, upon surrender of this Warrant at the principal offices of the Company, together with a duly executed subscription form in the form attached hereto as Exhibit 1 and simultaneous payment of an amount equal
to the product obtained by multiplying the Warrant Price by the number of Warrant Shares so purchased in lawful money of the United States. The Warrant Price and the number and character of Warrant Shares purchasable under this Warrant are subject
to adjustment as provided herein. 
 This Warrant has been issued pursuant to the terms of that certain equity purchase agreement (the
“Purchase Agreement”), dated as of [___], 2020, by and among the Company, Haymaker Acquisition Corp. II, a Delaware corporation, and each of the entities listed on Exhibit B attached thereto. Capitalized terms used but
not defined herein shall have the meanings ascribed to such terms in the Purchase Agreement. This Warrant replaces and supercedes Warrant Number [__], issued to the Holder on [____], 20[    ] (the “Original
Warrant”). The Holder acknowledges and agrees that the Original Warrant is hereby terminated and is no longer in force and effect. 

1. DEFINITIONS. The following definitions shall apply for purposes of this Warrant: 

“Affiliate” of a specified person means a person who, directly or indirectly through one or more intermediaries,
controls, is controlled by, or is under common control with, such specified person. 
 “A&R Certificate of
Incorporation” means that certain amended and restated certificate of incorporation of the Company, dated as of [___], 2020. 

“Business Day” means a day except a Saturday, a Sunday or other day on which the Securities and Exchange Commission or
banks in the City of New York or the State of Delaware are required by law to be closed. 
 “Company” shall
include, in addition to the Company identified in the opening paragraph of this Warrant, any corporation or other entity that succeeds to the Company’s obligations under this Warrant, whether by permitted assignment, by merger or consolidation
or otherwise. 
  

 “Common Stock” means shares of common stock of the Company, par
value $0.0001 per share. 
 “Company Organizational Documents” means the A&R Certificate of Incorporation and
the bylaws of the Company. 
 “Effective Date” means [___], 2020. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder, as they may be amended from time to time. 
 “Exercise Period” has the meaning set forth in
Section 2.1. 
 “Maturity Date” means the fifth anniversary of the Effective Date. 

“Warrant” means this Warrant and any warrant(s) delivered in substitution or exchange therefor, as provided herein.

 “Warrant Price” means $10.00 per Warrant Share, subject to adjustments as provided herein. 

“Warrant Shares” means [__] shares of Common Stock. The number and character of Warrant Shares are subject to
adjustment as provided herein. 
 2. EXERCISE. 

2.1 Exercisability of the Warrant. Subject to the terms and conditions of this Warrant, this Warrant may be exercised by
the Holder, in whole, from the Effective Date until the Maturity Date (such period, the “Exercise Period”). 

2.2 Method of Exercise. This Warrant shall be exercised by surrendering this Warrant at the principal offices of the
Company, with the subscription form attached hereto duly executed by the Holder, and by payment in a form specified in Section 2.3 of an amount equal to the product obtained by multiplying (i) the number of Warrant
Shares to be purchased by the Holder by (ii) the Warrant Price as determined in accordance with the terms hereof. 
 2.3
Form of Payment. Payment for the Warrant Shares upon exercise may be made, at the election of the Holder, by (a) a check payable to the Company’s order, (b) wire
transfer of funds to the Company, or (c) any combination of the foregoing. 
 2.4 Restrictions
on Exercise. This Warrant may not be exercised if the issuance of the Warrant Shares upon such exercise would constitute a violation of any applicable federal or state securities laws or other laws
or regulations. As a condition to the exercise of this Warrant, the Holder shall execute the subscription form attached hereto as Exhibit 1 confirming and acknowledging that the representations and warranties of the Holder set forth in
Section 4.1 of the Purchase Agreement are true and complete as of the date of exercise. 

  
 2 

 3. ISSUANCE OF WARRANT
SHARES. This Warrant shall be deemed to have been exercised immediately prior to the close of business on the date of its surrender for exercise as provided above, and the person entitled to receive the Warrant Shares issuable upon such
exercise shall be treated for all purposes as the holder of record of such Warrant Shares as of the close of business on such date. As soon as practicable on or after such date (in any event within five (5) Business Days), and if the shares of
Common Stock are then certificated, the Company shall issue and deliver to the person or persons entitled to receive the same a certificate or certificates for the number of Warrant Shares issuable upon such exercise. 

4. RIGHTS ATTACHING TO THE WARRANT SHARES. The Warrant Shares issued pursuant to the exercise of the Warrants shall be
validly issued, fully paid and non-assessable. 
 5. RESERVED. 

6. ADJUSTMENT PROVISIONS. The number and character of the Warrant Shares
issuable upon exercise of this Warrant and the Warrant Price therefor, are subject to adjustment upon each event in Sections 6.1 through 6.3 occurring between the Effective Date and the earlier of the time that it is exercised
or the Maturity Date: 
 6.1 Adjustment for Splits; Subdivisions; and
Combinations. The Warrant Price and the number of Warrant Shares for which this Warrant remains exercisable shall each be proportionally adjusted on an equitable basis in the event that the Company (i) forward splits or subdivides its
outstanding shares of Common Stock into a greater number of shares of Common Stock, or (ii) reverse splits or combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock. 

6.2 Adjustment for Reorganization,
Consolidation, Merger. (a) In case of any reclassification or reorganization of the Company or (b) in case the Company shall consolidate with or merge into one or more other corporations or
entities, in each case that results in the holders of Warrant Shares becoming entitled to receive stock or securities or property (in each case other than Warrant Shares) with respect to or in exchange for such Warrant Shares (each, a
“Reorganization Event”), then, and in each such case, the Holder, upon the exercise of this Warrant after such Reorganization Event shall be entitled to receive, in lieu of the Warrant Shares, the stock or other securities or
property which the Holder would have been entitled to receive upon such Reorganization Event if, immediately prior to such Reorganization Event, the Holder had completed such exercise of this Warrant, all subject to further adjustment as provided in
this Warrant. If after such Reorganization Event, the Warrant is exercisable for securities of a corporation or entity other than the Company, then such corporation or entity shall duly execute and deliver to the Holder a supplement hereto
acknowledging such corporation’s or other entity’s obligations under this Warrant; and in each such case, the terms of this Warrant shall be applicable to the shares of stock or other securities or property receivable upon the exercise of
this Warrant after the consummation of such Reorganization Event. 
 6.3 Conversion of Warrant
Shares. In case all (a) the authorized Warrant Shares are converted into other securities or property of the Company, or (b) the Warrant Shares otherwise cease to exist or to be authorized by the Company
Organizational Documents (each, a “Conversion Event”), then the Holder, upon exercise of this Warrant at any time after such Conversion Event, shall receive, in lieu of the number of Warrant Shares that would have been
issuable upon exercise of this Warrant immediately prior to such Conversion Event, the other securities or property of the Company that the Holder would have been entitled to receive upon the Conversion Event, if, immediately prior to such
Conversion Event, the Holder had completed such exercise of this Warrant. 

  
 3 

 6.4 Notice of
Adjustments. The Company shall promptly give written notice of each adjustment under this Section 6 of the Warrant Price or the number of Warrant Shares or other securities that remain issuable upon
exercise of this Warrant. The notice shall describe the adjustment and show in reasonable detail the facts on which the adjustment or readjustment is based. 

6.5 No Change Necessary. The form of this Warrant need not be
changed because of any adjustment in the Warrant Price or in the number of Warrant Shares issuable upon its exercise. 
 6.6
Fractional Shares. No fractional shares of Common Stock or strips representing fractional shares of Common Stock shall be issued upon the exercise of this Warrant. With respect to any fraction of a share of Common Stock
called for upon any exercise hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the fair market value of a share of Common Stock. 

7. COVENANTS OF THE COMPANY. 

7.1 No Impairment. The Company will not, by amendment of the Company Organizational Documents, or through reorganization,
consolidation, merger, dissolution, issue or sale of securities, sale of assets or any other voluntary action, willfully avoid or seek to avoid the observance or performance of any of the material terms of this Warrant, but will at all times in good
faith assist in the carrying out of all such material terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder against wrongful impairment. Without limiting the generality of the
foregoing, the Company will take all such action as may be necessary in order that the Company may duly and validly issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant. 

7.2 Reservation of Warrant Shares. The Company further covenants and agrees that the Company will, at all times during the
Exercise Period, take such corporate or other requisite action as required in order to have authorized and reserved, free from preemptive rights, a sufficient number of Warrant Shares to satisfy the exercise of this Warrant from time to time as
these Warrants are presented for exercise in accordance with the terms hereof. If, at any time during the Exercise Period, the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant, the
Company will promptly take such corporate or other requisite action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes.
The Company covenants and agrees that all Warrant Shares that may be issued upon the exercise of this Warrant in accordance with the terms hereof will be duly authorized, validly issued, fully paid,
non-assessable, free from all taxes, liens and charges with respect to the issuance thereof and free and clear of preemptive rights. 

8. GENERAL PROVISIONS. 

8.1 Transfer Restrictions of the Warrant. This Warrant and all rights hereunder may not be transferred by the
Holder, in whole or in part, without the written consent of the Company, which written consent may be withheld or given in the Company’s sole discretion; provided, however, no such written consent of the Company shall be required with
respect to a transfer of this Warrant by the Holder to an Affiliate thereof, provided however that any such transferee shall enter into a written agreement with the Company agreeing to be bound by the transfer restrictions set forth in this Warrant.
Any purported transfer of this Warrant in violation of this Section 8.1 shall be null and void ab initio, and the Company shall refuse to recognize any such transfer for any purpose and shall not reflect in its records any
change in record ownership pursuant to any such transfer. 

  
 4 

 8.2 No Voting
or Other Rights. This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder or other securityholder of the Company. In the absence of
valid exercise of this Warrant, no provisions of this Warrant, and no enumeration herein of the rights or privileges of the Holder, shall cause the Holder to be a stockholder or other securityholder of the Company for any purpose. 

8.3 Governing Law. This Warrant shall be governed by, and construed in accordance with, the
laws of the State of Delaware. The parties hereto irrevocably consent to the exclusive jurisdiction of the (a) federal courts located in the State of Delaware, and (b) the state courts of the State of Delaware, for the settlement of any
disputes that arise under this Agreement. Each of the parties hereto waives any objection to the venue in any such proceeding, whether on the grounds of forum non-conveniens or otherwise. 

8.4 Headings. The headings and captions used in this Warrant are used only for convenience and are not to be considered in
construing or interpreting this Warrant. All references in this Warrant to sections and exhibits shall, unless otherwise provided, refer to sections hereof and exhibits attached hereto, all of which exhibits are incorporated herein by this
reference. 
 8.5 Notices. Unless otherwise provided herein, any notice required or permitted under this Warrant shall
be given in writing and shall be deemed effectively given (a) at the time of personal delivery, if delivery is in person; (b) one (1) Business Day after deposit with an express overnight courier for United States deliveries, or three
(3) Business Days after deposit with an international express overnight air courier for deliveries outside of the United States, in each case with proof of delivery from the courier requested; or (c) four (4) Business Days after deposit in
the United States mail by certified mail (return receipt requested) for United States deliveries, when addressed to the party to be notified at the address listed on the signature page (or at such other address as it may designate by notice in
writing to the Holder) and to the Holder at its address of record in the Company’s books and records, or at such other address as the Company or the Holder may designate by ten (10) days advance written notice to the other party hereto.

 8.6 Amendment; Waiver. Any term of this Warrant may from time to time be amended,
modified or waived (either generally or in a particular instance and either retroactively or prospectively) by the Company and the Holder. No waivers of any term, condition or provision of this Warrant, in any one or more instances, shall be deemed
to be, or construed as, a further or continuing waiver of any such term, condition or provision. 
 8.7 Severability. If
one or more provisions of this Warrant are held to be unenforceable under applicable law, then such provision(s) shall be excluded from this Warrant to the extent they are unenforceable and the remainder of the Warrant shall be interpreted as if
such provision(s) were so excluded and shall be enforceable in accordance with its terms. 
 [Signature page follows] 

  
 5 

 IN WITNESS WHEREOF, the parties hereto have executed this Warrant as of the date
first written above. 
  

			
	THE COMPANY:
	
	ARKO Corp.
		
	By:	 	  

		 	
	Name:	 	  

		 	
	Title:	 	  

		 	
	By:	 	  

		 	
	Name:	 	  

		 	
	Title:	 	  

		 	
	HOLDER:
	
	[___________]
		
	By:	 	  

		 	
	Name:	 	  

		 	
	Title:	 	  

 EXHIBIT 1 

FORM OF SUBSCRIPTION 

(To be completed and signed only upon exercise of the Warrant) 

To: ARKO Corp., a Delaware corporation (the “Company”) 

We refer to that certain Warrant of the Company, Warrant No. ___, issued on [__], 2020 (the “Warrant”). Defined terms
used but not defined herein shall have the meaning set forth in the Warrant. 

❒    Cash Exercise. On the terms and conditions set forth in the Warrant,
the undersigned Holder hereby elects to purchase _________ Warrant Shares of the Company (the “Warrant Shares”), pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price for
such shares of Common Stock in full. 
 In exercising the Warrant, the undersigned Holder hereby confirms and acknowledges that the
representations and warranties set forth in Section 4.1 of the Purchase Agreement as they apply to the undersigned Holder continue to be true and complete as of this date. Please issue a certificate or certificates representing such Warrant
Shares in Holder’s name and deliver such certificate(s) to Holder at the address set forth below: 
  

	
	  

	(Address)
	
	  

	(City, State, Zip Code)
	
	  

	(Federal Tax Identification Number)

 WHEREFORE, the undersigned Holder has executed and delivered the Warrant and this Subscription Form as
of the date set forth below. 
  

							
	Date:                                     
                                         
            	 		 	[INSERT HOLDER’S NAME]
				
		 		 	By:	 	
                     
                                        

				
		 		 	Its:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]